 0 Table of Contents |
  1 Home |
  2 GA4GH |
  3 Genomic Diagnostics |
  4 Deep phenotyping |
  5 Modeling phenotypic data |
  6 Human Phenotype Ontology |
  7 Examples |
  8 Artifacts Summary |
   8.1 service-request-supporting-info |
   8.2 Biosample |
   8.3 Disease profile |
   8.4 Individual |
   8.5 Measurement |
   8.6 Phenopacket profile |
   8.7 Phenopackets Genomic Interpretation |
   8.8 Phenopackets Variant |
   8.9 Phenotypic Feature |
   8.10 Treatment |
   8.11 ACMG Pathogenicity Classification |
   8.12 Additional Variant Identifier |
   8.13 Coded Onset |
   8.14 Diagnostic Marker |
   8.15 Filter Status |
   8.16 Histological Diagnosis |
   8.17 Interpretation Status |
   8.18 Karyotypic Sex |
   8.19 Material Sample |
   8.20 Measurement (Biosample) |
   8.21 Molecule Context |
   8.22 Onset |
   8.23 Pathological TNM Finding |
   8.24 Pathological Tumor Stage |
   8.25 Phenotypic Feature (Biosample) |
   8.26 Phred Quality Score |
   8.27 Related Concept ID |
   8.28 Taxonomy |
   8.29 Therapeutic Actionability |
   8.30 Tumor Grade |
   8.31 Tumor Progression |
   8.32 VCF Info |
   8.33 VRS Object |
   8.34 ACMG Pathogenicity Classification Value Set |
   8.35 Diagnostic Marker |
   8.36 GENO Ontology Allelic State Value Set |
   8.37 HistologicalDiagnosis |
   8.38 Hpo Severity Value Set |
   8.39 Interpretation Status Value Set |
   8.40 Karyotypic sex value set |
   8.41 Molecule Context Value Set |
   8.42 Observation categories |
   8.43 Observation Codes for status of a PhenotypicFeature |
   8.44 Onset ValueSet |
   8.45 Phenotypic abnormality ValueSet |
   8.46 Phenotypic component ValueSet |
   8.47 Phenotypic modifier ValueSet |
   8.48 Sequence Ontology Structural Variant Value Set |
   8.49 Taxonomy |
   8.50 Therapeutic Actionability Value Set |
   8.51 Tumor Grade |
   8.52 Tumor Progression |
   8.53 Tumor Stage |
   8.54 Categories |
   8.55 Categories |
   8.56 HTS Format |
   8.57 Karyotypic sex code system |
   8.58 Section Type |
   8.59 A VALID karyotypic sex Observation instance. |
   8.60 A valid phenotypic abnormality Observation example. |
   8.61 amyotrophy |
   8.62 An INVALID karyotypic sex Observation instance. |
   8.63 An INVALID phenotypic abnormality Observation example. |
   8.64 arachnodactyly |
   8.65 bladderCarcinoma |
   8.66 CHF-stageIII |
   8.67 CHF-with-severity |
   8.68 example-patient |
   8.69 excluded-disease |
   8.70 fiberSizeVariability |
   8.71 globalDevelopmentalDelay |
   8.72 hypotonia |
   8.73 intellectualDisabilityDisease |
   8.74 longPhiltrum |
   8.75 losartan |
   8.76 lowSetEars |
   8.77 lvdysfunction-excluded |
   8.78 microphthalmia |
   8.79 muscleBiopsy |
   8.80 muscleWeakness |
   8.81 MVP-with-onset |
   8.82 PeterGeneticist |
   8.83 Phenopacket (static snapshot of clinical findings to support differential diagnosis of a child with developmental delay). |
   8.84 phenopacket Patient Example01 |
   8.85 phenopacket Practitioner Example01 |
   8.86 phenopacket Specimen Example01 |
   8.87 Phenopackets Genomic Interpretation Example-1 |
   8.88 Phenopackets Genomic Interpretation Example-2 |
   8.89 Phenopackets Variant Example-1 |
   8.90 PhenopacketsBundleExample01 |
   8.91 Polydactyly-with-modifier |
   8.92 Proband1 |
   8.93 reducedVisualAcuity |
   8.94 retinalDetachment |
   8.95 tga |
   8.96 This is an example of a composition resource that represents some of the Phenopackets data elements |
   8.97 thrombocytopenia |
   8.98 vitreoretinochoroidopathy |